CG Oncology, Inc. Common stock
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinic… Read more
Market Cap & Net Worth: CG Oncology, Inc. Common stock (CGON)
CG Oncology, Inc. Common stock (NASDAQ:CGON) has a market capitalization of $5.56 Billion ($5.56 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3042 globally and #2050 in its home market, demonstrating a 6.50% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CG Oncology, Inc. Common stock's stock price $65.90 by its total outstanding shares 84435200 (84.44 Million).
CG Oncology, Inc. Common stock Market Cap History: 2024 to 2026
CG Oncology, Inc. Common stock's market capitalization history from 2024 to 2026. Data shows growth from $2.42 Billion to $5.56 Billion (30.69% CAGR).
Index Memberships
CG Oncology, Inc. Common stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.20% | #68 of 976 |
|
NASDAQ Composite
IXIC
|
$33.26 Trillion | 0.01% | #371 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.28% | #45 of 263 |
Weight: CG Oncology, Inc. Common stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CG Oncology, Inc. Common stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CG Oncology, Inc. Common stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
867.76x
CG Oncology, Inc. Common stock's market cap is 867.76 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $2.42 Billion | $1.14 Million | -$88.04 Million | 2123.85x | N/A |
| 2025 | $3.51 Billion | $4.04 Million | -$161.00 Million | 867.76x | N/A |
Competitor Companies of CGON by Market Capitalization
Companies near CG Oncology, Inc. Common stock in the global market cap rankings as of March 18, 2026.
Key companies related to CG Oncology, Inc. Common stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
CG Oncology, Inc. Common stock Historical Marketcap From 2024 to 2026
Between 2024 and today, CG Oncology, Inc. Common stock's market cap moved from $2.42 Billion to $ 5.56 Billion, with a yearly change of 30.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.56 Billion | +58.72% |
| 2025 | $3.51 Billion | +44.92% |
| 2024 | $2.42 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of CG Oncology, Inc. Common stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.56 Billion USD |
| MoneyControl | $5.56 Billion USD |
| MarketWatch | $5.56 Billion USD |
| marketcap.company | $5.56 Billion USD |
| Reuters | $5.56 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.